Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
XOMA Royalty Corp operates as a biotech royalty aggregator, acquiring economic interests in pre-commercial and commercial therapeutic products developed by other companies. The company generates revenue through milestone payments and royalties on product sales without conducting its own R&D, creating a capital-efficient model with minimal operating expenses. Its portfolio includes rights to multiple clinical and commercial-stage assets across oncology, immunology, and other therapeutic areas.
XOMA acquires royalty rights and economic interests in drug candidates at discounted valuations, typically from biotech companies needing non-dilutive capital. Revenue materializes when underlying products achieve regulatory milestones or generate commercial sales, with XOMA receiving contractual percentages (typically low-to-mid single digits on sales). The model requires minimal ongoing capital expenditure and no R&D spending, creating high gross margins (99%+) but lumpy revenue dependent on partner success. Competitive advantage lies in deal sourcing capabilities, due diligence expertise in assessing clinical/commercial risk, and access to capital for opportunistic acquisitions.
Clinical trial results for underlying portfolio assets (positive Phase 3 data drives milestone payments and increases NPV of future royalties)
FDA or EMA regulatory approval decisions for partner products (triggers milestone payments and initiates royalty streams)
Commercial launch performance and sales trajectory of royalty-bearing products
New royalty acquisition announcements and portfolio expansion deals
Partner company financial health and ability to fund development programs
Binary clinical trial outcomes create extreme revenue volatility - single Phase 3 failure can eliminate years of expected cash flows from a major asset
Patent expiration and biosimilar competition erode royalty streams on commercial products, with limited ability to replace mature assets
Regulatory pathway changes or heightened FDA scrutiny can delay approvals and milestone payments across the portfolio
Increasing competition from specialized pharma royalty funds (RPRX, HZNP) and private equity bidding up acquisition prices and compressing returns
Partner companies may prioritize internal programs over licensed assets, reducing commercial investment and sales potential for XOMA's royalty-bearing products
Negative operating cash flow ($-0.0B TTM) and FCF requires external financing or asset monetization to fund operations and new acquisitions
Debt/Equity of 1.22 creates refinancing risk if credit markets tighten or if portfolio underperforms and asset values decline
Current ratio of 3.91 provides near-term liquidity cushion, but burn rate sustainability depends on timing of milestone receipts
low - Royalty revenue is driven by pharmaceutical sales which are largely non-discretionary and insulated from economic cycles. However, partner companies' ability to raise capital for clinical development can be affected by broader biotech funding conditions during recessions.
Rising rates negatively impact valuation through higher discount rates applied to long-duration royalty cash flows (similar to bonds). Higher rates also tighten biotech venture funding, potentially slowing partner companies' development timelines and delaying milestone/royalty payments. The company's modest debt load (D/E 1.22) creates some refinancing risk but limited direct interest expense impact.
Moderate - XOMA's ability to acquire new royalties depends on access to debt or equity capital markets. Tighter credit conditions reduce acquisition capacity and may force reliance on more dilutive equity financing. Partner company creditworthiness matters indirectly, as financially distressed partners may delay trials or fail to commercialize products.
growth - Investors seek exposure to diversified biotech upside without single-company binary risk, attracted by potential for exponential royalty growth if multiple assets succeed. The 498.7% YoY revenue growth (off small base) and negative cash flow profile appeal to risk-tolerant growth investors willing to accept volatility for asymmetric return potential. Not suitable for income investors given no dividend and cash consumption.
high - Stock exhibits extreme volatility driven by binary clinical/regulatory events beyond company control. Recent 24.2% decline over 3 months reflects typical drawdowns. Small market cap ($0.3B) and low liquidity amplify price swings on news flow.
